Goldfinch Bio Announces Appointment of Robin A. Walker, J.D., as Chief Legal Officer

11.19.2020

CAMBRIDGE, Mass. – November 19, 2020 – Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Robin A. Walker, J.D, as Chief Legal Officer, effective immediately. Ms. Walker will be a member of the executive management team and lead the company’s legal organization, including its corporate governance and compliance functions.

“With Robin’s appointment, we continue to strengthen our corporate leadership and build out key functions to support the advancement of our pipeline of precision medicine product candidates for people living with severe and debilitating kidney diseases,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Robin brings to Goldfinch Bio deep knowledge of the biotechnology industry and a proven track record of building legal organizations within companies developing novel therapeutics for orphan and rare diseases. I believe her guidance will be critical as we continue to explore the full potential of our world-class product engine to uncover the genetic drivers of kidney disease and inform our growing clinical- and research-stage portfolio.”

“I am pleased to join Goldfinch Bio at such an important stage of growth and development,” said Ms. Walker. “With GFB-887 in Phase 2 clinical development and an investigational new drug application for GFB-024 expected in 2021, the company is making meaningful progress toward realizing its mission to protect patients from the inevitability of dialysis and kidney transplant, as well as the associated physical, emotional and financial burdens of kidney diseases.  I look forward to contributing to this mission-driven company and supporting its future progress.”

An accomplished biotechnology executive and lawyer, Ms. Walker brings over 20 years of in-house and major law firm experience, having worked with several companies to support the research, development, approval, launch and commercialization of orphan and rare disease products. She joins Goldfinch Bio from Stoke Therapeutics, where she served as Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary. In that role, Ms. Walker was responsible for corporate governance and overall management of the legal and compliance functions, and for developing and implementing scalable legal operations processes and systems. Prior to Stoke, Ms. Walker served as Senior Vice President, Head of Legal at Casebia Therapeutics, where she designed and oversaw all aspects of the company’s legal strategy and provided counsel on corporate, governance, employment, compliance and regulatory matters. Previously, she was Associate General Counsel, Corporate, at Biogen Inc., where she provided day-to-day support across a variety of business operations. Earlier in her career, Ms. Walker was Senior Corporate Counsel at Staples, Inc., and a Corporate Associate in the Boston office of K&L Gates.

Additionally, Ms. Walker sits on the Board of Directors of the Northeast Chapter of the Association of Corporate Counsel, the Kendall Square Association and the Shady Hill School, and serves on the Dean’s Advisory Committee at Boston University School of Law. She holds her J.D. from Boston University School of Law, and her B.A. in History from Vassar College.

 

About Goldfinch Bio
Goldfinch Bio, Inc. is a precision-based kidney medicines company focused on improving the lives of patients suffering from severe and debilitating kidney diseases. Our precision medicine discovery engine allows us to discover and validate novel targets aimed at overcoming the challenge of heterogeneity in diverse kidney disease patient populations to identify subsets most likely to respond to treatment. Using this approach, we are building a robust drug pipeline of novel, precision medicine product candidates. Our lead candidate, GFB-887, which is currently being evaluated in the TRACTION-2 Phase 2 clinical study, is a podocyte-targeting therapy designed specifically to treat patients with kidney diseases characterized by an over-activation of the TRPC5-Rac1 pathway. In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies.  Visit us at www.goldfinchbio.com to learn more.

Goldfinch Bio Contacts:

Investors: Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media: Liz Melone
lmelone@goldfinchbio.com